Future investigations using genome-wide approaches—such as chromatin immunoprecipitation sequencing (ChIP-seq) or transcriptomic profiling following EGR3 perturbation—will be critical to fully define the EGR3 regulatory network and its multifaceted role in GBM progression. This evidence concerns the gene EGR3 and glioblastoma.